Moore's law for membranous nephropathy.

Abstract

The identification of target antigens in membranous nephropathy has accelerated since the report of M-type phospholipase A2 receptor 1 (PLA2R1). One could say that technological advances have allowed for the demonstration of Moore's law (a doubling every 2 years in the number of transistors that can be fit onto a computer chip) in the field of membranous nephropathy, and that even more antigens can be expected in the near future. In this issue of Kidney International, Sethi et al. describe semaphorin-3B as a novel target antigen, defining a type of membranous nephropathy with onset in the pediatric population.